Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05669820 | Antisecretory Factor Glioblastoma Phase 2(AFGB2) | recruiting | Phase 2 / Phase 3 | 300 | Peter SiesjöOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07291102 | Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma | not yet recruiting | Phase 3 | 96 | Nationwide Children's HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04681417 | Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome(RETINO 2018) | recruiting | Phase 2 / Phase 3 | 225 | Institut CurieOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04250922 | LAM561 With RT and TMZ for Adults With Glioblastoma(CLINGLIO) | active not recruiting | Phase 2 / Phase 3 | 144 | Laminar PharmaceuticalsINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT02685605 | Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme(INTRAGO-II) | active not recruiting | Phase 3 | 314 | Universitätsmedizin MannheimOTHER | 8 | Oct 14, 2025 | clinicaltrials |
| NCT00807027 | Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea | completed | Phase 3 | 180 | GC Cell CorporationINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT01351870 | Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma (PNET4)(SIOP-PNET-4) | completed | Phase 3 | 52 | Institut CurieOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01811121 | MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS(RESECT) | completed | Phase 3 | 170 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT00186888 | Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma | completed | Phase 3 | 107 | St. Jude Children's Research HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03149575 | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM(STAR-3) | terminated | Phase 3 | 2 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03345095 | A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma(MIRAGE) | completed | Phase 3 | 749 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Jul 1, 2025 | clinicaltrials |
| NCT05439278 | Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma | recruiting | Phase 3 | 178 | Severance HospitalOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT03632135 | Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma(CSCRGBM) | completed | Phase 3 | 78 | Cordgenics, LLCINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT02017717 | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients(CheckMate 143) | completed | Phase 3 | 529 | Bristol-Myers SquibbINDUSTRY | 12 | Apr 4, 2025 | clinicaltrials |
| NCT06749925 | Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma | not yet recruiting | Phase 3 | 186 | University of Sao Paulo General HospitalOTHER | 0 | Apr 1, 2025 | clinicaltrials |
| NCT06830421 | Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients(PRIMA-CNS) | recruiting | Phase 3 | 340 | University Hospital FreiburgOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05118776 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | active not recruiting | Phase 3 | 136 | Ascletis Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06477939 | Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients(THREE-GLEES) | not yet recruiting | Phase 3 | 554 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT00653068 | Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System | completed | Phase 3 | 70 | Children's Oncology GroupNETWORK | 3 | Apr 23, 2024 | clinicaltrials |
| NCT03776071 | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | completed | Phase 3 | 260 | Denovo Biopharma LLCINDUSTRY | 3 | Apr 22, 2024 | clinicaltrials |
| NCT05318612 | Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)(EMITT) | active not recruiting | Phase 3 | 238 | Radboud University Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT01906814 | Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation | unknown | Phase 3 | 179 | Sun Yat-sen UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT02546102 | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | suspended | Phase 3 | 234 | Precision Life Sciences GroupINDUSTRY | 3 | Apr 3, 2024 | clinicaltrials |
| NCT03548571 | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy(DEN-STEM) | unknown | Phase 2 / Phase 3 | 60 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | completed | Phase 2 / Phase 3 | 101 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT03275402 | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases | terminated | Phase 2 / Phase 3 | 52 | Y-mAbs TherapeuticsINDUSTRY | 4 | Feb 13, 2024 | clinicaltrials |
| NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | completed | Phase 3 | 221 | Sumitomo Pharma America, Inc.INDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT00716976 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | completed | Phase 3 | 131 | Children's Oncology GroupNETWORK | 3 | Nov 9, 2023 | clinicaltrials |
| NCT06071897 | Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma | recruiting | Phase 3 | 15 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT01728155 | European Low and Intermediate Risk Neuroblastoma Protocol | completed | Phase 3 | 685 | Instituto de Investigacion Sanitaria La FeOTHER | 10 | Sep 8, 2023 | clinicaltrials |
| NCT04532229 | Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | unknown | Phase 3 | 48 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05718466 | Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy | completed | Phase 3 | 35 | Henry Ford Health SystemOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT00548756 | Randomized Trial Comparing Radiosurgery With vs Without Whole Brain Radiotherapy | completed | Phase 3 | 152 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification(Intellance1) | completed | Phase 3 | 691 | AbbVieINDUSTRY | 28 | May 11, 2023 | clinicaltrials |
| NCT00033293 | Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma | completed | Phase 3 | 53 | Children's Oncology GroupNETWORK | 3 | Apr 18, 2023 | clinicaltrials |
| NCT05100641 | AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM | not yet recruiting | Phase 3 | 672 | Aivita Biomedical, Inc.INDUSTRY | 0 | Apr 10, 2023 | clinicaltrials |
| NCT02617589 | An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)(CheckMate 498) | completed | Phase 3 | 560 | Bristol-Myers SquibbINDUSTRY | 19 | Mar 28, 2023 | clinicaltrials |
| NCT03291977 | Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)(FLEGME) | completed | Phase 3 | 51 | Rennes University HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05600491 | A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme | unknown | Phase 3 | 78 | Sun Yat-sen UniversityOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05493228 | Dexmedetomidine Infusion on Intraoperative Propofol,Fentanyl Requirements in Spine Surgery for Pediatric Cancer Patients | unknown | Phase 3 | 38 | Children's Cancer Hospital Egypt 57357OTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03243461 | International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)(HIT-HGG-2013) | unknown | Phase 3 | 167 | University of GöttingenOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer(GBM) | unknown | Phase 3 | 348 | Northwest BiotherapeuticsINDUSTRY | 4 | May 18, 2022 | clinicaltrials |
| NCT00346164 | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma | completed | Phase 3 | 588 | Children's Oncology GroupNETWORK | 5 | Apr 28, 2022 | clinicaltrials |
| NCT00567567 | Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | completed | Phase 3 | 665 | Children's Oncology GroupNETWORK | 6 | Apr 28, 2022 | clinicaltrials |
| NCT05334238 | Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | unknown | Phase 3 | 174 | Ruijin HospitalOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02313389 | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma(BLOCAGE-01) | unknown | Phase 3 | 428 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients(STELLAR) | unknown | Phase 3 | 343 | Orbus Therapeutics, Inc.INDUSTRY | 8 | Jan 21, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jan 9, 2026source: clinicaltrials